The Medicine Cabinet Math
Picture the person you see all the time: mid-50s, nagging back pain, a bottle of acetaminophen in one hand and naproxen in the other, trying to remember what they took at 8 a.m. and whether it’s safe to layer on the other. On July 24, 2026, the FDA approved a product built for exactly that person: Tylenol with Naproxen, the first over-the-counter tablet to combine acetaminophen and naproxen sodium in one pill.
The Number to Get Right
Kenvue markets a 650 mg acetaminophen / 220 mg naproxen sodium combination, accurate, but that’s the full dose. The FDA actually approved a tablet of acetaminophen 325 mg and naproxen sodium 110 mg, so the advertised dose is two tablets, taken every 12 hours. It’s cleared for adults and children 12 and up for minor aches from headache, backache, muscular aches, toothache, menstrual cramps, and minor arthritis pain. Anyone who reads “650 mg” and assumes one pill could easily double up; the tablet-versus-dose distinction is where accidental overshoots start.
Where “Superior” Gets Slippery
The mechanistic logic is sound: two drugs, two pathways, fast onset from acetaminophen plus a 12-hour NSAID tail from naproxen. The efficacy claim is where marketing outruns evidence. Kenvue cites eight studies showing the combo beats either drug alone, but those are manufacturer-cited, and the independent literature is mixed. A 2025 systematic review of 77 studies concluded that added benefit of acetaminophen/NSAID combinations should not be assumed. The advantage is context-dependent: strongest in dental and postsurgical pain, weakest in the musculoskeletal territory this product is largely aimed at, where a randomized trial found no added benefit from combining the two. Look at the label’s indications: backache, muscular aches, arthritis. Much of the intended everyday use sits exactly where the combination’s edge is least proven.
The Opioid Framing
Kenvue positions this as an opioid-free option, citing a figure that up to 1 in 4 patients prescribed opioids risk addiction. Handle that stat with care, its sourcing doesn’t cleanly trace through the medical literature. The opioid-sparing rationale for non-opioid pain relief is broadly sound, but whether this convenience combination meaningfully reduces opioid use is a hope, not a demonstrated result.
The Fine Print
Combining two ingredients into one tablet also combines their risks. Because it contains acetaminophen, it must not be used with other acetaminophen products, a real hazard given how many cold, flu, and sleep formulas hide it, as stacking can cause liver damage. Because it contains an NSAID, the label warns of stomach bleeding and increased risk of heart attack, heart failure, and stroke, all higher when used more or longer than directed.
The Real Takeaway
Convenience is exactly where quiet mistakes happen. A single simplified bottle removes the guesswork of coordinating two products, but also the visual cue of two separate bottles that might make someone pause before adding a cold medicine or PM sleep aid that hides the same ingredients. And the combination’s payoff depends on why you’re in pain: for a toothache, the evidence is on your side; for a flared-up back, a single agent taken correctly may work just as well, with the combo mostly adding cost and a second drug’s risks. None of that nuance is on the box.
Sources & Further Reading
FDA approval notice (July 24, 2026); Kenvue press release via PR Newswire (July 24, 2026). Strength and safety language from the FDA; the 650/220 figures reflect the manufacturer’s full dose (two 325/110 tablets). On efficacy: a 2025 systematic review of 77 studies finding added benefit should not be assumed, plus trial evidence of no added benefit in acute musculoskeletal pain.
